Abiopharma

RENTON HOLLINGS 🟢 acquired 9.5K shares (2 derivative) of ANAPTYSBIO, INC (ANAB) at $43.91 Transaction Date: Jan 06, 2026 | Filing ID: 000001

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025

Veeva to Present at the J.P. Morgan 2026 Healthcare Conference

Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology

Spyre Therapeutics Announces Grants of Inducement Awards

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of $218 Million, Moves to Net Cash Position and Reaffirms Full-Year Adjusted EBITDA Guidance

WAGNER CHARLES F JR 🟡 adjusted position in 9.5K shares (1 derivative) of VERTEX PHARMACEUTICALS INC / MA (VRTX) at $461.00 ($8.0M) Transaction Date: Jan 06, 2026 | Filing ID: 000002

Schmid John P. 🟢 acquired 9.5K shares (2 derivative) of ANAPTYSBIO, INC (ANAB) at $43.91 Transaction Date: Jan 06, 2026 | Filing ID: 000001

New Form SCHEDULE 13G/A - PLIANT THERAPEUTICS, INC. Filed: 2026-01-08 AccNo: 0000895421-26-000001 Size: 8 KB